Artificial intelligence-supported biotechnology startup Healx, $47 million received investment. The company’s $47 million series C investment round Atomic ve R42 jointly led. In the investment tour of UK-based Healx Ayana Capital, Balderton Capital, Btov, Global Brai, Jonathan Milner, O2h Ventures ve VU Venture Partners took place.
The company announced that it will use the new investment to develop its AI-supported drug discovery platform to find new treatments for rare diseases and operational expansion for clinical trials in the United States.
Healx in 2014 Tim Guilliams ve David Brown It stands out as a biotechnology company founded by and aims to develop new treatments for rare diseases. The company’s goal is to accelerate the drug discovery process by repurposing existing drugs and using artificial intelligence technologies.
Healx uses artificial intelligence technology to identify hidden connections between existing chemical compounds and drugs and potential treatment pathways. This process aims to create a comprehensive biomedical knowledge graph by combining public and private data sources. Thus, it offers more detailed and holistic information about diseases and treatment methods.
The traditional drug development process involves focusing on a specific molecular target and designing drugs suitable for this target. However, this process takes time and often has high failure rates. The method developed by Healx aims to accelerate this process by reusing existing drugs and finding alternative ways to treat rare diseases.
The company is currently working on a drug candidate called HLX-1502 for neurofibromatosis Type 1 (NF1) disease. This drug was derived from a drug that was developed for another disease but was not marketed in the United States. Healx plans to reformulate this drug and use it for nervous system diseases such as NF1.
Source link: https://webrazzi.com/2024/08/02/yapay-zeka-destekli-biyoteknoloji-girisimi-healx-47-milyon-dolar-yatirim-aldi/